WinSanTor is a clinical-stage biotechnology company focused on the discovery and development of treatments for peripheral neuropathies, including diabetic peripheral neuropathy, chemo-induced peripheral neuropathy and HIV-induced peripheral neuropathy. Learn more about WinSanTor and our mission.
We are developing a proprietary first-in-class therapy to prevent and reverse nerve damage. Our lead/first compound, WST-057, is a well-characterized, previously approved drug with an established safety history that has been used for many years against an unrelated indication. This allows us a direct path to market, reducing development, time, and cost with a drug that is patented as a new formulation with novel indications. Learn about our drug’s mechanism.
Interested in sharing your story with us? Fill out our peripheral neuropathy survey. Want to learn more about neuropathy? Our blog features topics ranging from how peripheral neuropathy affects sleep to its connections to diet, weather and rare diseases.
Questions? Email us or call 858-208-0546.
We are exploiting every strategy, mechanism, and regulation to accelerate approval of our drugs, including recycling a previously approved safe drug. By focusing on patient impact rather than the bottom line, we believe we’re creating a new sustainable model for pharma companies based on patient need, not just money.